Prelude Therapeutics Inc
PRLD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001678660
No open-market purchases or sales by Prelude Therapeutics Inc insiders were filed in the last 90 days; 75 institutions reported holding it in 13F filings for Q2 2026, worth $264.3M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Prelude Therapeutics Inc changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 61 | 1 | 70 | +10 |
| Shares | 33.9M | 1.07M | 35.8M | +2.91M (+8.8%) |
| Value | $129.2M | $4.07M | $74.0M | −$51.1M (−40.9%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (17)
Institutions that held Prelude Therapeutics Inc at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 1,058,316 | $2.19M | 0.00% |
| ExodusPoint Capital Management, LP | 921,621 | $1.91M | 0.02% |
| Avidity Partners Management LP | 890,000 | $1.84M | 0.09% |
| Marshall Wace, LLP | 359,137 | $743.4K | 0.00% |
| T. Rowe Price Investment Management, Inc. | 281,583 | $583.0K | 0.00% |
| Millennium Management LLC | 160,524 | $332.3K | 0.00% |
| XTX Topco Ltd | 48,239 | $99.9K | 0.01% |
| Cubist Systematic Strategies, LLC | 40,102 | $83.0K | 0.00% |
| Cerity Partners LLC | 32,875 | $68.1K | 0.00% |
| Sherbrooke Park Advisers LLC | 20,048 | $41.5K | 0.01% |
| Jump Financial, LLC | 15,534 | $32.2K | 0.00% |
| Verition Fund Management LLC | 11,295 | $23.4K | 0.00% |
| Simplex Trading, LLC | 9,332 | $19.0K | 0.00% |
| Point72 (DIFC) Ltd | 5,206 | $10.8K | 0.00% |
| Group One Trading, L.P. | 500 | $1.03K | 0.00% |
| Sterling Capital Management LLC | 42 | $87 | 0.00% |
| Capital Performance Advisors LLP | 8 | $17 | 0.00% |
Sold out (7)
Institutions that held Prelude Therapeutics Inc at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Sio Capital Management, LLC | 320,394 | $1.22M |
| Kennedy Capital Management, Inc. | 35,283 | $134.4K |
| Y-Intercept (Hong Kong) Ltd | 18,839 | $71.8K |
| State of Wisconsin Investment Board | 18,700 | $71.2K |
| Prelude Capital Management, LLC | 11,074 | $42.2K |
| Qube Research & Technologies Ltd | 3,126 | $11.9K |
| Nisa Investment Advisors, LLC | 2,100 | $8.00K |
Not filed for Q3 2024 yet (1)
Institutions that held Prelude Therapeutics Inc at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 1,068,916 | $4.07M |